<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Azelastine (nasal): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Azelastine (nasal): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Azelastine (nasal): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10814" href="/d/html/10814.html" rel="external">see "Azelastine (nasal): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="15940" href="/d/html/15940.html" rel="external">see "Azelastine (nasal): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7976934"><span class="drugH1">Brand Names: US</span>
<ul>
<li>AstePro Childrens [OTC];</li>
<li>Astepro [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F7976939"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Histamine H<sub>1</sub> Antagonist;</li>
<li>
                        Histamine H<sub>1</sub> Antagonist, Second Generation</li></ul></div>
<div class="block doa drugH1Div" id="F7977043"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c8123d5-63e1-4fd0-b4d4-fd52eac80de3">Allergic rhinitis, perennial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, perennial:</b>
<b>Intranasal: 0.15% solution (Rx or OTC):</b> 2 sprays in each nostril twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="493236ef-6c7e-43e1-b6af-a9ef049ee9c4">Allergic rhinitis, seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, seasonal:</b>
<b>Intranasal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>0.15% solution (Rx or OTC): </b>1 or 2 sprays in each nostril twice daily <b>or</b> 2 sprays in each nostril once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>0.1% solution:</b> 1 or 2 sprays in each nostril twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1820e284-41e2-4255-93fb-309e4d01aef5">Nonallergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonallergic rhinitis</b>
<b>:</b>
<b>Intranasal:</b>
<b>0.1% solution:</b> 2 sprays in each nostril twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991678"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doha drugH1Div" id="F50988993"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F7977044"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F7977042"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15940" href="/d/html/15940.html" rel="external">see "Azelastine (nasal): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c8123d5-63e1-4fd0-b4d4-fd52eac80de3">Allergic rhinitis, perennial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, perennial:</b> Intranasal:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;6 years: 0.1% solution: 1 spray <b>per nostril</b> twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years: 0.1% or 0.15% solution: 1 spray <b>per nostril</b> twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: 0.15% solution: 2 sprays <b>per nostril</b> twice daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="493236ef-6c7e-43e1-b6af-a9ef049ee9c4">Allergic rhinitis, seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, seasonal:</b> Intranasal:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;6 years: 0.1% solution: 1 spray <b>per nostril</b> twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years: 0.1% or 0.15% solution: 1 spray <b>per nostril</b> twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">0.1% solution: 1 or 2 sprays <b>per nostril</b> twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">0.15% solution: 1 or 2 sprays <b>per nostril</b> twice daily <b>or</b> 2 sprays <b>per nostril</b> once daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ddf38ef2-7f97-430e-8b5a-18e104711ed8">Vasomotor rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor rhinitis:</b> Intranasal: Children ≥12 years and Adolescents: 0.1% solution: 2 sprays <b>per nostril</b> twice daily</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51073346"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51073347"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F7976970"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Adverse reactions may be dose-, indication-, or product-dependent:</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Bitter taste (4% to 20%), headache (1% to 15%), drowsiness (≤12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Cold symptoms (children ≤17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (exacerbation; ≤17%), cough (children: 11%; infants and children: ≥2%)</p>
<p style="text-indent:0em;">2% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dysesthesia (8%), dizziness (2%), fatigue (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (children: 2% to 4%), nausea (3%), xerostomia (3%), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Upper respiratory tract infection (children: ≥2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (&lt;2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media (infants &amp; children: ≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (2% to 7%), asthma (5%), sinusitis (3% to &gt;5%), burning sensation of the nose (4%), pharyngitis (4%), nasal discomfort (≤4%), sneezing (1% to 3%), sore nose (infants and children: ≥2%), nasal mucosa ulcer (≤2%), pharyngolaryngeal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;2%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, hypertension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Abnormality in thinking, anxiety, depersonalization, depression, hypoesthesia, malaise, nervousness, sleep disorder, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczema, folliculitis, furunculosis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, amenorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, ageusia, aphthous stomatitis, constipation, diarrhea, gastroenteritis, glossitis, increased appetite, toothache</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, mastalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum ALT</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection, viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, dislocation of temporomandibular joint, hyperkinesia, limb pain, rheumatoid arthritis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye pain, watery eyes</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, bronchospasm, laryngitis, nasal congestion, paranasal sinus hypersecretion, paroxysmal nocturnal dyspnea, postnasal drip, sore throat</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Laceration</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Altered sense of smell, anaphylactoid reaction, anosmia, application site irritation, atrial fibrillation, blurred vision, chest pain, confusion, drug tolerance, dyspnea, facial edema, increased serum transaminases, insomnia, muscle spasm, nasal sores, palpitations, paresthesia, pruritus, skin rash, urinary retention, visual disturbance, xerophthalmia</p></div>
<div class="block coi drugH1Div" id="F7976967"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F7976968"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), do not use if prior allergic reaction to azelastine or any component of the formulation; notify health care provider prior to use if you have had recent nasal ulcers, surgery, or injury that has not healed. Discontinue use and notify health care provider if allergic reaction (eg, skin rash) or severe or frequent nosebleeds occur.</p></div>
<div class="block dosfc drugH1Div" id="F57083959"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">205.5 mcg/spray = 0.15% solution; 137 mcg/spray = 0.1% solution.</p></div>
<div class="block foc drugH1Div" id="F7977055"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Astepro: 205.5 mcg/spray (4 mL, 11 mL, 23 mL, 30 mL) [alcohol free, fragrance free, steroid free; contains benzalkonium chloride, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AstePro Childrens: 205.5 mcg/spray (4 mL, 11 mL, 23 mL) [alcohol free, fragrance free, steroid free; contains benzalkonium chloride, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 137 mcg/spray (30 mL); 0.1% (30 mL); 0.15% (30 mL)</p></div>
<div class="block geq drugH1Div" id="F7976937"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F7977057"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Azelastine HCl Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per mL): $3.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.15% (per mL): $1.20 - $4.64</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F7977046"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intranasal:</b> Before initial use of the nasal spray, the delivery system should be primed with 4 sprays (0.1% solution) or 6 sprays (0.15% solution [Rx or OTC]), or until a fine mist appears. If 3 or more days have elapsed since last use, the delivery system should be reprimed with 2 sprays or until a fine mist appears. Blow nose to clear nostrils. Keep head tilted downward when spraying. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Aim the spray tip toward the back of nose. Breathe in through nose. While inhaling, press pump to release spray. Alternate sprays between nostrils. After each use, wipe the spray tip with a clean tissue or cloth. Avoid spraying in eyes or mouth. Do not tilt head back after use. Discard bottle after number of sprays have been administered based on the package size (eg, 120 sprays, 200 sprays), even if not completely empty.</p></div>
<div class="block admp drugH1Div" id="F52614313"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For intranasal administration only. Before initial use, the delivery system should be primed until a fine mist appears; when 3 or more days have elapsed since the last use, the pump should be reprimed until a fine mist appears. Blow nose to clear nostrils. Remove the dust cover. Keep head tilted downward when spraying. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Alternate sprays between nostrils. After each use, wipe the spray tip with a clean tissue or cloth. Avoid spraying in eyes or mouth.</p></div>
<div class="block use drugH1Div" id="F7976942"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>OTC labeling:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Allergic rhinitis:</b> Temporary relief of nasal congestion, runny nose, sneezing, and itchy nose due to hay fever or other upper respiratory allergies in patients ≥6 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rx labeling:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonallergic rhinitis (azelastine [generic] 0.1% solution):</b> Relief of symptoms of nonallergic rhinitis in adults and adolescents ≥12 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Perennial allergic rhinitis (0.15% solution):</b> Relief of symptoms of perennial allergic rhinitis in patients ≥6 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Seasonal allergic rhinitis:</b> Relief of symptoms of seasonal allergic rhinitis in patients ≥6 years of age (<b>0.15% solution</b>) and ≥5 years of age (<b>0.1% solution</b>).</p></div>
<div class="block cyt drugH1Div" id="F7976976"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F7976977"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: Azelastine (Nasal) may enhance the CNS depressant effect of CNS Depressants. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F7976964"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">An increased risk of adverse pregnancy outcomes has not been observed; however, information related to the use of nasal azelastine in pregnancy is limited. Use of other agents for the treatment of allergic rhinitis in pregnant women may be preferred (BSACI [Scadding 2017]).</p></div>
<div class="block brc drugH1Div" id="F20547484"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">It is not known if azelastine is present in breast milk following nasal administration.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering azelastine (nasal) to breastfeeding women; the decision to breastfeed during therapy should consider the risk of infant exposure, benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block pha drugH1Div" id="F7977028"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competes with histamine for H<sub>1</sub>-receptor sites on effector cells and inhibits the release of histamine and other mediators involved in the allergic response; when used intranasally, reduces hyper-reactivity of the airways; increases the motility of bronchial epithelial cilia, improving mucociliary transport</p></div>
<div class="block phk drugH1Div" id="F7977030"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 15 minutes (Dykewicz 2020); maximum effect: 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 14.5 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Azelastine: ~88%; Desmethylazelastine: ~97%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP; active metabolite, desmethylazelastine.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~40%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Azelastine: 22 hours (0.1% solution), 25 hours (0.15% solution); Desmethylazelastine: 52 hours (0.1% solution), 57 hours (0.15% solution).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 2 to 3 hours (0.1% solution); 4 hours (median; 0.15% solution).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~75%, &lt;10% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 0.5 L/hour/kg.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961953"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Allergodil</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Allergodil | Nolen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Astepro</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Eze allergy</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Allergodil</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Allergodil</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Azelast | Aznite | Cloridrato de azelastina | Rino-azetin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Allergodil | Otrivin Heuschnupfen</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Allergodil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Allergodil</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Azep | Min qi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Azclor nl</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Allergodil | Azelsan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Allergodil | Allergodil gegen heuschnupfen</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Rinalin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Corifina</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Azep | Azetin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Vivispray</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Azep</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Azep</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Vividrin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Carelastin | Carelastin azelastine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Azep</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Allergodil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Azela | Azep</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Astelin | Azlasure | Azosin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Acatar allergy | Allergodil | Azelamed | Azelastin pos</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Astepro</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Allergodil Spray</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Allergodil</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Allergodil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Azep</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Allergodil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Azela | Azetin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Allergodil | Sanorin allergo</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Allergodyl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Astepro Allergy (azelastine) [package insert]. Whippany, NJ: Bayer HealthCare LLC; June 2022.</div>
</li>
<li>
<div class="reference">
                  Azelastine 0.1% spray [prescribing information]. Branchburg, NJ: Amneal Pharmaceuticals LLC; March 2021.</div>
</li>
<li>
<div class="reference">
                  Azelastine 0.15% spray [prescribing information]. Lake Forest, IL: Akorn; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol.</i> 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azelastine-nasal-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30239057">
<a name="30239057"></a>Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856‐889. doi:10.1111/cea.12953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azelastine-nasal-drug-information/abstract-text/30239057/pubmed" id="30239057" target="_blank">30239057</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8674 Version 284.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
